7.84
-0.19 (-2.37%)
Previous Close | 8.03 |
Open | 8.09 |
Volume | 2,026,948 |
Avg. Volume (3M) | 1,931,964 |
Market Cap | 1,977,538,048 |
Price / Earnings (Forward) | 370.37 |
Price / Sales | 2.63 |
Price / Book | 2.21 |
52 Weeks Range | |
Earnings Date | 7 Nov 2024 |
Profit Margin | -81.13% |
Operating Margin (TTM) | -23.09% |
Diluted EPS (TTM) | -1.67 |
Quarterly Revenue Growth (YOY) | -2.50% |
Total Debt/Equity (MRQ) | 100.03% |
Current Ratio (MRQ) | 10.74 |
Operating Cash Flow (TTM) | 29.89 M |
Levered Free Cash Flow (TTM) | 8.86 M |
Return on Assets (TTM) | -1.61% |
Return on Equity (TTM) | -42.93% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | Maravai LifeSciences Holdings, | Bearish | Bullish |
AIStockmoo Score
Analyst Consensus | -0.5 |
Insider Activity | 0.0 |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -2.0 |
Average | -0.40 |
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Growth |
% Held by Insiders | 1.45% |
% Held by Institutions | 102.69% |
52 Weeks Range | ||
Price Target Range | ||
High | 13.00 (RBC Capital, 65.82%) | Buy |
Median | 9.00 (14.80%) | |
Low | 4.25 (Goldman Sachs, -45.79%) | Sell |
Average | 8.75 (11.61%) | |
Total | 2 Buy, 1 Sell | |
Avg. Price @ Call | 5.08 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Goldman Sachs | 05 Dec 2024 | 4.25 (-45.79%) | Sell | 5.09 |
08 Oct 2024 | 7.00 (-10.71%) | Hold | 7.68 | |
Baird | 08 Nov 2024 | 9.00 (14.80%) | Buy | 5.08 |
RBC Capital | 08 Nov 2024 | 13.00 (65.82%) | Buy | 5.08 |
Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
---|---|---|---|---|
ECKERT R ANDREW | 5.58 | - | 134,409 | 750,002 |
LUCIER GREGORY T | 5.43 | 5.43 | 0 | 0 |
Aggregate Net Quantity | 134,409 | |||
Aggregate Net Value ($) | 750,002 | |||
Aggregate Avg. Buy ($) | 5.51 | |||
Aggregate Avg. Sell ($) | 5.43 |
Name | Holder | Date | Type | Quantity | Price | Value ($) |
---|---|---|---|---|---|---|
ECKERT R ANDREW | Director | 16 Dec 2024 | Acquired (+) | 134,409 | 5.58 | 750,002 |
LUCIER GREGORY T | Director | 09 Dec 2024 | Disposed (-) | 20,645 | 5.43 | 112,102 |
LUCIER GREGORY T | Director | 09 Dec 2024 | Acquired (+) | 20,645 | 5.43 | 112,102 |
Date | Type | Details |
---|---|---|
05 Dec 2024 | Announcement | Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors |
12 Nov 2024 | Announcement | Maravai LifeSciences Announces November 2024 Investor Conference Schedule |
07 Nov 2024 | Announcement | Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research |
07 Nov 2024 | Announcement | Maravai LifeSciences Reports Third Quarter 2024 Financial Results |
15 Oct 2024 | Announcement | Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024 |
24 Sep 2024 | Announcement | TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |